Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
BERKELEY HEIGHTS, N.J., April 21, 2017 -- Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies in the management of acute, life-threatening conditions, today announced it will host a conference call on Wednesday, May 3, 2017 at 8:30 a.m. ET to discuss its first quarter 2017 financial results.
The conference call will be available via phone and webcast. To access the call, please dial (877) 388-5691, or (562) 350-0788 for international callers, and reference participant code 7855024 approximately 15 minutes prior to the call. A replay of the call may be accessed through May 17, 2017 on the investor section of Edge’s website or by dialing (855) 859-2056, or (404) 537-3406 for international callers, and referencing participant code 7855024. A live webcast of the conference call will be available on the investor relations section of Edge’s website at www.edgetherapeutics.com.
About Edge Therapeutics, Inc.
Edge Therapeutics, Inc. is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms for the management of acute, life-threatening neurological and other conditions. EG-1962, Edge’s lead product candidate, has the potential to fundamentally improve patient outcomes and transform the management of aneurysmal subarachnoid hemorrhage, which is bleeding around the brain due to a ruptured brain aneurysm. Edge is evaluating EG-1962 in two clinical studies: a pivotal Phase 3 NEWTON 2 study of EG-1962 delivered via external ventricular drain, and a study of direct intracisternal administration of EG-1962. For additional information about Edge, please visit www.edgetherapeutics.com.
Forward-Looking Statements
This press release and any statements of representatives of Edge Therapeutics, Inc. related thereto that are not historical in nature contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, without limitation, statements with respect to Edge’s plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," “seeks,” "intends," "plans," "potential" or similar expressions, including statements with respect to Edge’s future clinical plans, Edge’s ability to advance its portfolio of therapies towards commercialization and the potential effects of its products. These statements are based upon the current beliefs and expectations of Edge’s management and are subject to significant risks and uncertainties. Actual results may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various risk factors (many of which are beyond Edge's control) as described under the heading "Risk Factors" in Edge’s filings with the United States Securities and Exchange Commission.
Investor Contact: Gregory Gin Edge Therapeutics, Inc. Tel: 1-800-208-EDGE (3343) Email: [email protected] Media Contact: Laura Bagby 6 Degrees Tel: 312-448-8098 Email: [email protected]
